VolitionRx Limited prepaid $500,000 in cash toward the outstanding principal balance of its senior secured convertible promissory note issued to Lind Global Asset Management XII LLC. Following this partial prepayment, the remaining balance on the $2.4 million note is reduced to $706,667. In connection with the transaction, Lind agreed to defer monthly repayments for November and December 2026 and waived its conversion rights until January 1, 2027, unless the stock price reaches at least $0.275 per share. This brings total debt reduction across both notes held by Lind to over $5.0 million since June 30, 2026. VolitionRx Limited is a multi-national epigenetics company developing blood tests for early disease detection and monitoring.
